Acute hepatotoxicity after excessively high doses of carbamazepine on two occasions.
A 2 1/2-year-old child being treated with carbamazepine (CBZ) for a seizure disorder on two separate occasions experienced elevated CBZ serum concentrations (28 and 23.2 mg/L), severe liver damage (SGOT greater than 6000 IU, SGPT greater than 5000 IU), and central nervous system manifestations (coma, lethargy, seizures). During the first episode, the time course of CBZ concentrations exhibited a nonlinear decline and was accompanied by CBZ-10,11-epoxide concentrations that were elevated 4-fold compared to normal values. Cerebrospinal fluid concentrations of CBZ and CBZ-10,11-epoxide were also elevated, although their ratios to serum concentrations did not suggest enhanced permeability of the central nervous system to these substances. The concentrations of CBZ-10,11-epoxide but not CBZ were elevated for the duration of time that the patient was comatose, suggesting that this metabolite may contribute to the neurotoxic side effects observed with CBZ therapy.
D000410:Alanine Transaminase / Q000097:blood; D000641:Ammonia / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002220:Carbamazepine / Q000097:blood / Q000506:poisoning* / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000097:blood / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000097:blood; D010672:Phenytoin / Q000097:blood / Q000627:therapeutic use; D012640:Seizures / Q000097:blood / Q000188:drug therapy
D002220:Carbamazepine; D010672:Phenytoin; D000641:Ammonia; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase